重组人骨形态发生蛋白-7与脱钙骨基质复合物双重骨诱导作用的生物学评价

将不同剂量的重组人骨形态发生蛋白-7(rhBMP-7)与脱钙骨基质(DBM)分别复合后,植入小鼠股部内侧肌间隙,三周后取材,通过组织学检查、碱性磷酸酶(ALP)及钙含量的测定比较各组的骨诱导活性。结果显示,三组复合物均有骨组织生成,中、高剂量组可见骨小梁、板层骨和原始骨髓腔,血管和骨髓丰富;低剂量组的成骨量明显少于中、高剂量组,且新骨的成熟度低于其他两组,DBM少部分吸收;单独植入rhBMP-7组有编织骨形成;而DBM组可见成骨细胞的聚集。rhBMP-7/DBM复合组在ALP和Ca含量水平上与同等剂量的两对照组相比均有显著性差异(P<0.01),而rhBMP-7三种剂量之间均有显著性差异(P<0.01)。这充分说明DBM作为rhBMP-7的合适载体,具有缓释作用,且二者复合可起到双重骨诱导活性;而且rhBMP-7的骨诱导活性具有一定的剂量依赖性。     

rhBMP-2基因转染小鼠间充质干细胞的成骨活性和BMP-2的释放规律分析

通过pcDNA3.1-rh BMP-2质粒转染小鼠间充质干细胞C3H10T1/2研究其成骨能力和增殖效应,探讨BMP-2的释放规律。将预先准备好的重组rhBMP-2质粒转染至C3H10T1/2细胞,利用G418抗药性筛查转染成功的细胞。将研究实验细胞分为转染组、空载组、空白组。通过ELISA检测各组细胞上清液中的BMP-2含量,CCK-8试剂盒检测各组细胞的增值活性,通过测定ALP活性和进行ALP、钙茜素红染色,检测各组细胞成骨活性。结果显示转染组BMP-2浓度随着时间推移逐渐达到高峰并维持一段时间,各检测点均明显高于空白组和空载组(p0.05),转染组细胞较其余两组更具增殖活性、成骨活性(p0.05)。此结果表明C3H10T1/2细胞是pcDNA3.1/rhBMP-2重组质粒的良好宿主,转染后能在一定时间内平稳和持续地表达外源性BMP-2,有较强诱导细胞成骨分化能力。     

大肠杆菌中高效表达rhBMP-4的探讨及初步活性测定

目的 在大肠杆菌中表达具有生物活性的rhBMP-4。方法 在不改变氨基酸序列的前提下,以全基因合成的方式对人BMP-4成熟肽基因全长进行定点突变,将之重组入pET-3c表达载体并转化至大肠杆菌BL21(DE)plysS。IPTG诱导和包涵体复性后,利用C2C12细胞横向成骨细胞分化实验以及小鼠肌袋异位骨形成实验检测其活性。 结果 获得0.348 kb的BMP-4 DNA序列,表达的目的蛋白主要以包涵体的形式存在。经纯化及复性后,体内与体外的活性检测表明rhBMP-4有良好的诱骨生成活性。结论 该方案能够实现rhBMP-4在大肠杆菌中的高效表达。     

细辛挥发油镇痛作用机制的初步实验研究

目的:研究细辛挥发油的镇痛作用机制.方法:用水蒸气蒸馏法提取细辛挥发油成分,将其配制成不同剂量组,检测乙酸致痛小鼠脑组织和血清中NO、PGE2、MDA含量以及NOS和SOD活性.结果:细辛挥发油提取物能使乙酸致痛小鼠脑组织和血清中NO、PGE2、MDA含量及NOS活性明显降低,SOD活性明显增强.结论:细辛挥发油的镇痛作用机制可能与降低NO、PGE2、MDA含量及NOS活性.提高SOD活性有关.     

氟骨症不同动物模型的建立与评价

目的 为选择合适的实验动物并建立氟骨症动物模型,研究不同动物对氟化物致骨骼损伤的敏感性.方法 分别选取离乳新西兰兔、Hartley豚鼠、Wistar大鼠、KM小鼠各16只,每种动物随机分为两组,每组8只,即对照组(C):饲喂标准饲料,饮用去离子水;模型组(M):饲喂标准饲料,饮用150 mg/L氟化钠(NaF)去离子水.在饲喂60 d后取股骨制作组织切片观察组织形态变化,并测定股骨骨氟、骨钙、骨磷的含量及血清碱性磷酸酶(ALP)活性.结果 与对照组相比,各种实验动物模型组生长发育受到显著的抑制,股骨形态破坏明显,骨矿化显著减少,骨氟含量显著升高,血清ALP活性显著增强,但股骨钙和磷含量差异无显著性(P＞0.05).结论 高氟可不同程度的损害豚鼠、家兔、小鼠、大鼠的生长发育及骨骼系统,导致产生氟骨症,但综合考察,以豚鼠、家兔较为敏感,其次为小鼠、大鼠.     

原花青素对磷酸三钙磨损颗粒所致小鼠颅骨溶解的干预作用及其机制

目的:研究原花青素对磷酸三钙(TCP)磨损颗粒诱导小鼠颅骨溶解的保护作用,并探讨其机制。方法:48只雄性ICR小鼠,随机分为假手术(Sham)组、TCP磨损颗粒(TCP)组、原花青素(0.2mg/kg,1mg/kg,5mg/kg)组,每组12只。将TCP磨损颗粒30mg包埋于小鼠颅骨顶部构建假体周围模型,于术后第2日颅顶局部注射原花青素,隔日1次。2周后处死小鼠采血、取颅骨。抗酒石酸酸性磷酸酶(TRAP)染色和HE染色观察假体周围骨溶解和破骨细胞生成情况;实时荧光定量PCR检测假体周围骨组织中破骨细胞调控基因TRAP、capthesinK、c-Fos和NFATc1的mRNA水平;化学比色法检测血清中丙二醛(MDA)和总抗氧化能力(T-AOC)含量及超氧化物歧化酶(SOD)活性;Westernblot法检测小鼠假体周围骨组织中自噬标志蛋白Beclin-1和微管相关蛋白1轻链3(LC-3)表达变化。结果:与Sham组比较,TCP组假体周围骨溶解面积、破骨细胞生成及其调控基因mRNA水平显著增加(P<0.05),血清MDA含量均明显升高、T-AOC水平和SOD活性明显降低(P<0.05),假体周围骨组织中Beclin-1和LC-3均表达显著上调、LC-3I向LC-3II转换明显增加(P<0.05)。与TCP组比较,原花青素组假体周围骨溶解面积、破骨细胞生成及其上述调控基因、血清MDA含量明显减少(P<0.05),血清T-AOC含量和SOD活性显著增加(P<0.05)且Beclin-1和LC-3等蛋白表达及LC-3I向LC-3II转换也明显下调。结论:原花青素对TCP磨损颗粒所致的假体周围骨溶解具有明显保护作用,其机制可能与减轻氧化应激反应和自噬的活化密切相关。     

不同剂量rhBMP-2/CPC 体内骨诱导活性的比较研究*

目的:对比不同剂量rhBMP-2与多孔CPC复合后的诱导成骨效应,探讨与多孔CPC复合后的rhBMP-2的量效关系.方法:将0.5 mg/ml、1 mg/ml、2 mg/ml、3 mg/ml 4种不同剂量的rhBMP-2与多孔CPC材料复合后,植入36只小鼠双侧股部肌肉内,分别于术后1周、2周及4周取材,通过大体观察、组织学分析、形态计量学分析、荧光双标测定,观察4组诱导成骨情况.结果:植入1周,rhBMP-2与多孔CPC材料复合表现出了较明显的剂量依赖性,含有较多rhBMP-2的材料内诱导形成的骨组织也较多,但骨组织的增加并未随着rhBMP-2剂量的增加而连续递增,2 mg组和3 mg组新生骨组织含量无明显差异(P＞0.05).植入4周,新生骨组织向材料内部生长,但此时的新生骨组织面积较2周增加不显著(P＞0.05).0.5 mg组新生骨组织含量仍处于最低水平,而其它三组之间却无明显差异(P＞0.05).结论:在0.5 mg/ml-2.0 mg/ml剂量范围,与多孔CPC复合的rhBMP-2诱导成骨量与其剂量成正比,最佳剂量为2 mg/ml.     

大豆卵磷脂对小鼠的抗疲劳和抗氧化作用研究

目的:研究大豆卵磷脂的抗疲劳及抗氧化作用。方法:小鼠经口给予大豆卵磷脂30天后,采用负重游泳实验,观察记录小鼠游泳死亡时间;检测血清尿素氮、肝糖原;测定血清和肝匀浆超氧化物歧化酶(SOD)活性、谷胱甘肽过氧化物酶(GSH-Px)活力、丙二醛(MDA)含量。结果:给予大豆卵磷脂后,与对照组相比,实验组小鼠负重游泳时间明显延长,肝糖原消耗量减少,降低运动后血清尿素氮水平(P<0.05);升高小鼠血清和肝匀浆SOD活性及GSH-Px活力,降低MDA的含量(P<0.05)。结论:大豆卵磷脂具有抗疲劳和抗氧化作用。     

氧化应激对磷酸三钙磨损颗粒诱导的假体周围骨溶解的影响及其机制

目的：探讨氧化应激对磷酸三钙（TCP）磨损颗粒诱导的假体周围骨溶解的影响及其作用机制。方法：36只雄性ICR小鼠随机分为3组（n=12）：假手术（Sham）组、TCP磨损颗粒（TCP）组和N-乙酰-L-半胱氨酸（NAC）组。将TCP磨损颗粒30 mg包埋于小鼠颅骨顶部构建假体周围骨溶解模型,于术后第2天颅顶骨膜局部注射NAC（1.0 mg/kg）,隔日1次,持续2周后处死动物采血、取颅骨。抗酒石酸酸性磷酸酶（TRAP）染色观察小鼠颅骨假体周围骨溶解情况;ELISA和化学比色法检测血清中肿瘤坏死因子-α（TNF-α）、白介素-1β（IL-1β）、白介素-6（IL-6）和总抗氧化能力（T-AOC）含量及超氧化物歧化酶（SOD）活性;Western blot检测假体周围骨组织中内质网应激标志蛋白葡萄糖调节蛋白78（GRP78）、蛋白激酶R样内质网激酶（PERK）、磷酸化PERK（p-PERK）、真核细胞翻译起始因子2α（eIF2α）和磷酸化eIF2α（p-eIF2α）的表达。结果：与Sham组比较,TCP组小鼠血清TNF-α、IL-1β和IL-6水平及假体周围骨溶解面积显著增加（P<0.05）,T-AOC含量和SOD活性明显降低（P<0.05）,GRP78蛋白质表达、p-PERK/PERK和p-eIF2α/eIF2α值显著升高。与TCP组比较,NAC组小鼠血清TNF-α、IL-1β和IL-6水平及骨溶解面积明显减少（P<0.05）,血清T-AOC含量和SOD活性明显增加（P<0.05）,GRP78蛋白质表达、p-PERK/PERK和p-eIF2α/eIF2α值明显降低。结论：抑制氧化应激可阻止TCP磨损颗粒诱导的假体周围骨溶解,其机制可能与PERK/eIF2α通路的失活有关。     

人骨形成蛋白-7成熟肽基因在巴斯德毕氏酵母中的分泌表达

目的:利用甲醇酵母表达系统,构建重组人骨形成蛋白-7(rhBMP-7)成熟肽的基因工程菌,并实现其分泌表达。方法:采用PCR方法,依据GenBank数据库中hBMP-7成熟肽序列(AccessionNo.NM_001719)设计并合成一对引物,从已构建的含hBMP-7的克隆载体中扩增获得人骨形成蛋白-7成熟肽基因片段,并以pPIC9K为表达载体构建重组表达质粒,电转化巴斯德毕氏酵母SMD1168,于30℃进行甲醇诱导分泌表达,经筛选获得rhBMP-7成熟肽表达株,并进行了表达产物的活性测定。结果:表达产物存在于培养上清中,约占分泌蛋白总量的8%。经Western印迹分析可以检测到重组表达产物,ELISA检测其具有特异性结合活性。结论:构建了重组人骨形成蛋白-7成熟肽的基因工程菌并在甲醇酵母中实现了分泌表达,为进一步的活性及功能研究奠定了基础。     

Ectopic bone formation in titanium mesh loaded with bone morphogenetic protein and coated with calcium phosphate

The osteoinductive properties of porous titanium fiber mesh, with or without a calcium phosphate coating and loaded with recombinant human bone morphogenic protein-2 (rhBMP-2) or rhBMP-2 and native bovine BMP (S-300) were investigated in a rat ectopic assay model. A total of 112 calcium phosphate-coated and 112 noncoated porous titanium implants, either loaded with rhBMP-2 and S-300 or loaded with rhBMP-2 alone, were subcutaneously placed in 56 Wistar-King rats. The rats were killed 5, 10, 20, and 40 days postoperatively, and the implants were retrieved.Histologic analysis demonstrated that all growth factor and carrier combinations induced ectopic cartilage and bone formation at 5 and 10 days, respectively. At 20 days, bone formation increased and was characterized by trabecular bone and bone marrow-like tissue. At 40 days, more lamellar bone and hemopoietic bone marrow-like tissue were present. At both times, more bone had been formed in calcium phosphate-coated implants than in noncoated samples. Further, in rhBMP-2 and S-300-loaded specimens, bone formation was higher than in rhBMP-2 only-loaded specimens. In rhBMP-2 only-loaded specimens, bone formation was mainly localized inside the mesh material, whereas in specimens loaded with both rhBMP-2 and S-300, the bone was localized inside and surrounding the titanium mesh. The histological findings were confirmed by calcium content and alkaline phosphatase activity measurements. In addition, all specimens showed osteocalcin expression as early as 5 days postoperatively.Our results show that the combination of titanium mesh with BMPs can induce ectopic bone formation and that this bone formation seems to be similar to "enchondral" ossification. In addition, a thin calcium phosphate coating can have a beneficial effect on the bone-inducing properties of a scaffold material. Finally, rhBMP-2 and native BMP act synergistically in ectopic bone induction.     

Dot-ELISA法检测血液及唾液HIV抗体的应用评价

评价人类免疫缺陷病毒1+2型抗体检测试剂盒(Dot-ELISA法)检测血清和唾液样本的临床性能。采用对照试验研究,选取背景清晰的研究对象200例,采集同一研究对象的血清和唾液样本,应用万泰生物药业公司生产的人类免疫缺陷病毒1+2型抗体检测试剂盒作为考核试剂,法国生物梅里埃公司生产的人类免疫缺陷病毒抗体诊断试剂盒(ELISA法)作为参考试剂,考核试剂检测结果与参考试剂及研究对象背景进行比较分析。考核试剂检测血清HIV抗体与参考试剂相比较,阳性符合率100%,阴性符合率100%,总符合率100%,Kappa值1.00,一致性为最强;考核试剂检测唾液HIV抗体与参考试剂检测结果相比较,阳性符合率98.78%,阴性符合率100%,总符合率99.50%,Kappa值0.99,一致性为最强。Dot-ELISA法人类免疫缺陷病毒1+2型抗体检测试剂盒对血清及唾液样本检测性能优越,适合HIV抗体快速筛查。     

Production of the recombinant human bone morphogenetic protein-2 in Escherichia coli and testing of its biological activity in vitro and in vivo

Bone morphogenetic protein-2 (rhBMP-2) represents the osteoinductive protein factor which plays a dominant role in growth and regeneration of a bone tissue. In clinical practice the bone grafting materials on the basis of rhBMP-2 are widely applied; the Russian analogues of similar materials are not produced. The fragment of the bmp2gene coding for a mature protein was cloned in Escherichia coli. The effective overproducing strain of rhBMP-2 was created on a basis of the E. coli BL21 (DE3). The rhBMP-2 production was about 25% of total cell protein. The biologically active dimeric form of rhBMP-2 was obtained by isolation and purification of protein from inclusion bodies with subsequent refolding. The rhBMP-2 sample with more than 80% of the dimeric form was obtained, which is able to interact with specific antibodies to BMP-2. Biological activity of the received rhBMP-2 samples was shown in the in vitro experiments by induction of alkaline phosphatase synthesis in C2C12 and C3H10T1/2 cell cultures. On model of the ectopic osteogenesis it was shown that received rhBMP-2 possesses biological activity in vivo, causing tissue calcification in the place of an injection. The protein activity in vivo depends on way of protein introduction and characteristics of protein sample: rhBMP-2 may be introduced in an acid or basic buffer solution, with or without the carrier. The offered method of rhBMP-2 isolation and purification results in increasing common protein yield as well as the maintenance of biologically active dimeric form in comparison with the analogues described in the literature.     

Accelerating Bone Generation and Bone Mineralization in the Interparietal Sutures of Rats Using an rhBMP-2/ACS Composite after Rapid Expansion

This study aims to investigate the effects of rhBMP-2/ACS composite on bone regeneration and mineralization during expansion of the interparietal suture in rats. Forty 10-week-old Sprague-Dawley rats were divided into four groups (n=10). The first group (intact group) did not receive any intervention. The second group (expansion control group) received an expansion force of 60 g. The remaining two groups received an expansion force of 60 g and were implanted with an atelo-type I absorbable collagen sponge and rhBMP-2/ACS composite positioned on the suture beneath the periosteum. The relapse, relapse ratio, relevant bone remodelling, and calcium and osteocalcin contents were evaluated. Bone regeneration in the interparietal suture was estimated by the histological method. The osteocalcin content was measured by radioimmunoassay, and the calcium content was measured by atomic absorption spectrophotometry. Bone regeneration was more active in the suture after application of the expansion force compared with that of the suture without any intervention. Bone bridges formed in the rhBMP-2/collagen composite group. Both osteocalcin and calcium content were higher in the rhBMP-2/collagen composite group than in the other three groups (P<0.01). The relapse ratio in the rhBMP-2/collagen group was much lower than that in the other two expansion groups (P<0.01). RhBMP-2/ACS composite can promote bone regeneration and bone mineralization in the expanded suture and decrease the relapse ratio. Thus, the rhBMP-2/ACS composite may be therapeutically beneficial to the inhibition of relapse and shortening of the retention period during rapid expansion.     

Osteogenic differentiation of pre-osteoblasts on biomimetic tyrosine-derived polycarbonate scaffolds

The osteogenic potential of biomimetic tyrosine-derived polycarbonate (TyrPC) scaffolds containing either an ethyl ester or a methyl ester group combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) was assessed using the preosteoblast cell line MC3T3-E1. Each composition of TyrPC was fabricated into 3D porous scaffolds with a bimodal pore distribution of micropores <20 μm and macropores between 200 and 400 μm. Scanning electron microscopy (SEM) characterization suggested MC3T3-E1 cell attachment on the TyrPC scaffold surface. Moreover, the 3D TyrPC-containing ethyl ester side chains supported osteogenic lineage progression, alkaline phosphatase (ALP), and osteocalcin (OCN) expression as well as an increase in calcium content compared with the scaffolds containing the methyl ester group. The release profiles of rhBMP-2 from the 3D TyrPC scaffolds by 15 days suggested a biphasic rhBMP-2 release. There was no significant difference in bioactivity between rhBMP-2 releasate from the scaffolds and exogenous rhBMP-2. Lastly, the TyrPC containing rhBMP-2 promoted more ALP activity and mineralization of MC3T3-E1 cells compared with TyrPC without rhBMP-2. Consequently, the data strongly suggest that TyrPC scaffolds will provide a highly useful platform for bone tissue engineering.     

Effects of bone morphogenetic protein-2 on human neonatal calvaria cell differentiation

Bone morphogenetic proteins (BMPs) are factors that promote osteoblastic cell differentiation and osteogenesis. It is unknown whether BMPs may act on human osteoblastic cells by increasing immature cell growth and/or differentiation. We investigated the short- and long-term effects of recombinant human (rh)BMP-2 on cell growth and osteoblast phenotype in a new model of human neonatal pre-osteoblastic calvaria cells (HNC). In short-term culture, rhBMP-2 (20-100 ng/ml) inhibited DNA synthesis and increased alkaline phosphatase (ALP) activity without affecting osteocalcin (OC) production. When cultured for 3 weeks in the presence of ascorbic acid and inorganic phosphate to induce cell differentiation, HNC cells initially proliferated, type 1 collagen mRNA and protein levels rose, and then decreased, whereas OC mRNA and protein levels, and calcium accumulation into the extracellular matrix increased at 2 to 3 weeks. A transient treatment with rhBMP-2 (50 ng/ml) for 1 to 7 days which affected immature HNC cells, decreased cell growth, increased ALP activity and mRNA, and induced cells to express ALP, osteopontin, and OC at 7 days, as shown by immunocytochemistry. At 2 to 3 weeks, matrix mineralization was markedly increased despite cessation of treatment, and although OC and Col 1 mRNA and protein levels were not changed. A continuous treatment with rhBMP-2 for 3 weeks which affected immature and mature cells reduced cell growth, increased ALP activity and mRNA at 1 week and increased OC mRNA and protein levels and calcium content in the matrix at 3 weeks, indicating complete osteoblast differentiation. These results indicate that the differentiating effects of BMP-2 on human neonatal calvaria are dependent on duration of exposure. Although long-term exposure led to complete differentiation of OC-synthesizing osteoblasts, the primary effect of rhBMP-2 was to promote osteoblast marker expression in immature cells, which was sufficient to induce optimal matrix mineralization independently of cell growth and type 1 collagen expression.     

Biotinated bone morphogenetic protein-2: In vivo and in vitro activity.

Recombinant human bone morphogenetic protein-2 (rhBMP-2) was biotinated, and the bioactivity of biotinated protein was assessed in vitro (alkaline phosphate induction in limb bud cells) and in vivo (osteoinduction in the rat ectopic assay). Amino-biotinated rhBMP-2 exhibited an increase in bioactivity whereas carboxy-biotinated rhBMP-2 did not exhibit any changes in bioactivity in vitro. Avidin inhibited the bioactivity of amino-biotinated but not carboxyl-biotinated rhBMP-2. Both amino- and carboxy-modified rhBMP-2 induced bone at an equivalent level to that of unmodified rhBMP-2 in vivo. The presence of avidin did not affect the osteoinductive activity of both types of biotinated rhBMP-2. The overall results indicated that binding to a large protein, avidin, might affect rhBMP-2 activity in vitro depending on the binding site; however, in vivo activity was unaffected by the avidin binding.     

Pleiotrophin regulates bone morphogenetic protein (BMP)-induced ectopic osteogenesis

We previously isolated pleiotrophin (PTN) from bovine bone as a protein and showed that it stimulated osteoblastic growth and differentiation. Further details of its function, however, have not been fully clarified. The aim of this paper was to elucidate the effects of PTN on bone morphogenetic protein (BMP)-induced ectopic osteogenesis. Recombinant human BMP (rhBMP)-2 (1.2 microg) was combined with a fibrous glass membrane, which had been established as an effective carrier. Various amounts of the purified bovine PTN (5, 10, 50, and 100 microg) or rhPTN (5 and 10 microg) were added to the rhBMP-2/carrier composites and implanted into rats subcutaneously as reported. It was found that the amount of bone induced in the system increased with the addition of 10 microg of either purified PTN or rhPTN. However, the amount of bone decreased with the addition of 50 or 100 microg of purified PTN dose-dependently, as judged by both alkaline phosphatase activity and calcium content in the retrieved implants. It was concluded that purified PTN or rhPTN, at ratios of concentration of 10-100 microg of PTN to 1.2 microg of rhBMP-2 in the carrier, regulated the ectopic bone-inducing activity of rhBMP-2.     

Administration of parathyroid hormone, prostaglandin E2, or 1-alpha,25-dihydroxyvitamin D3 restores the bone inductive activity of rhBMP-2 in aged rats

Bone morphogenetic protein (BMP) induces bone formation in young rodents, but aging causes a reduction in the bone-forming ability of BMP. Most patients who require bone reconstruction are relatively old. Accordingly, we examined whether anabolic hormones could restore the bone inductive activity of rhBMP-2 in aged rats. rhBMP-2 in a carrier pellet was implanted subcutaneously in both 4- and 50-week-old female Wistar rats. PTH, PGE2, or 1,25(OH)2D3 was injected every day during the period of BMP implantation. The pellets were harvested, and were examined both histologically and biochemically 2 weeks after implantation. Bone-forming ability was measured by alkaline phosphatase (ALP) activity and calcium (Ca) content. Pellets in 50-week-old rats showed a significant reduction in bone formation compared to pellets in 4-week-old rats. However, daily injections of PTH into 50-week-old rats restored both ALP activity (103 +/- 4.6%) and Ca content (105 +/- 2.6%). 1,25(OH)2D3 and PGE2 also restored Ca content (103 +/- 4.5% and 98 +/- 3.8%, respectively) and stimulated ALP activity (142 +/- 2.3% and 133 +/- 3.6%). These results show that the administration of these hormones restores bone-forming ability in aged rats. A combination treatment of these hormones with rhBMP-2 might be applicable to the reconstruction of bone defects in elderly patients.     

重组人骨形态发生蛋白-6的表达、纯化及其活性分析

利用RT-PCR从人胎盘组织中获取BMP-6成熟肽的cDNA 片段,并克隆到表达载体pET-15b中, 构建hBMP_6成熟肽的非融合蛋白表达质粒pET-BMP6,转化E.coli BL21（DE3）。IPTG 诱导4h后,工程菌高表达rhBMP-6成熟肽,在SDS-PAGE上出现预期的新蛋白带(≈15kD), 约占菌体总蛋白的10%,表达产物以包涵体形式存在。分离和纯化的包涵体溶解于8 mol/L尿素,在变性溶解状态下经阳离子交换层析,得到目的蛋白纯度达95%以上。再经稀释复性后,约80%的rhBMP-6形成同源二聚体。体外活性分析结果显示：rhBMP-6可以提高C3H10T1/2 细胞碱性磷酸酶活性及促进I型胶原、Osterix（Osx）和骨钙素（Osteocalcin）等成骨细胞表型转化标记基因mRNA的表达,证明制备的rhBMP_6具有诱导非骨源性细胞分化成为成骨细胞的作用。